T/CPHARMA 003-2020 Active Group standards

T/CPHARMA 003-2020 Chinese Drug Cost-Effectiveness Evaluation Guidelines 2020

Publish Date: 2020-11-28 Implement Date: 2020-11-29 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Out of stock

Basic Information

Standard Code: T/CPHARMA 003-2020

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: Standardized management and general provisions

ICS Name: Terminology (principles and coordination and cooperation)

Publish Date: 2020-11-28

Implement Date: 2020-11-29

Scope

Main Technical Content: Pharmacoeconomics is an interdisciplinary field that studies how to use limited drug resources to achieve maximum health improvement. It applies the theoretical foundation of applied economics to systematically and scientifically compare and analyze the economic costs and health outcomes of medical technologies, thereby forming the optimal solutions needed for decision-making, with the aim of improving the overall efficiency of drug resource allocation. Pharmaceutical policy issues are a key focus of China's current healthcare reform. Relevant national decision-making departments attach great importance to this and increasingly recognize the important role of pharmacoeconomic evaluation in basic health systems, universal health care systems, and national essential drug policies. In 2009, the "Opinions of the CPC Central Committee and the State Council on Deepening the Reform of the Medical and Health System" proposed establishing a "scientific and reasonable mechanism for drug pricing" and "gradually implementing a pre-pricing pharmacoeconomic evaluation system for new drugs and patented drugs". In 2016, the CPC Central Committee and the State Council issued the "Healthy China 2030" development plan, which explicitly called for establishing and improving an application-oriented outcome evaluation and technology assessment mechanism. At the same time, the "13th Five-Year Plan for Deepening the Reform of the Medical and Health System" also emphasized using pharmacoeconomic evaluation as an important basis for drug price negotiations. In 2017, pharmacoeconomic evaluation evidence was listed as an important basis for national medical insurance catalogue access negotiations. In 2019, the National Medical Security Administration issued the "2019 National Medical Insurance Drug Catalogue Adjustment Work Plan", which specifically stated that "similar drugs should be compared according to pharmacoeconomic principles, and priority should be given to